18 September 2017 (Reuters [Tom Miles])-Next month, the World Health Organization (WHO) will launch a strategy to stop cholera transmission by 2030, as an unprecedented outbreak in Yemen raced toward 700 000 suspected cases with little sign of slowing down. The WHO is also trying to keep the lid on a flare-up in Nigeria while tackling many entrenched outbreaks in Africa and an epidemic in Haiti, where almost 10 000 people have died since 2010.
Epidemics often arise in war zones. The WHO is sending an expert to Bangladesh to assess the risk for Rohingya Muslims fleeing from violence in Myanmar.
In Yemen, the most explosive outbreak on record has caused 686 783 suspected cases and 2090 deaths since late April. The number of deaths has slowed, but the spread of disease has not. In the past week, there were 40 000 suspected cases; the most for 7 weeks.
The number of suspected cases in Yemen cannot be checked accurately. Many cases may be acute watery diarrhea, which has similar symptoms and treatment but is not caused by the cholera bacterium, which is spread by contaminated food and water.
The WHO estimates there are 2.9 million cases of cholera and 95 000 deaths globally each year, far more than officially reported.
Equipped with a vaccine stockpile that it created in 2013, WHO plans to launch a global strategy on October 4. The aim is to use the vaccine to contain outbreaks as fast as possible, while addressing deeper problems.
In Africa, growing urbanization, climate change, conflict, displacement camps, as well as sanitation investment that is a third of what it should be, mean there is no reason to expect any improvement without deliberate action, stated Dominique Legros, WHO member of the Department for pandemic and epidemic diseases.
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Editorial comment: On average, more than 5000 cases a day have been occurring recently in Yemen. The number of cases reported in Yemen in 1 year is approaching 800 000, which is the number of cases that occurred (and are still occurring) in Haiti in 7 years. In Yemen, 23% of cases have been children aged <5 years and 54% have been children aged <18 years. One third of the deaths have been children.
FDA Panel Unanimously Recommends GSK Shingles Vaccine
13 September 2017 (Reuters [Bill Berkrot])-A US Food and Drug Administration advisory panel voted 11 to 0 that the safety and efficacy of GlaxoSmithKline's Shingrix shingles vaccine warrants approval for its use in adults aged ≥50 years.
Panel members said they were "very impressed" by efficacy data from Shingrix clinical trials and that it represents an improvement over Zostavax, the only marketed shingles prevention vaccine from Merck and Co.
Shingrix contains a component from Agenus Inc., sued to help boost efficacy.
In clinical trials, Shingrix showed greater protection against shingles among older recipients than that demonstrated by Zostavax. Four years after injection, the GSK vaccine remained about 90% effective in people aged >70 years, while the efficacy of Zostavax declines noticeably over time.
"This is a new generation of vaccine, which really has overcome the age-related decline in immunity, " Thomas Breuer, chief medical officer of GSK Vaccines, said in an interview. Shingrix, given in 2 doses 2 months apart, also reduces the incidence of postherpetic neuralgia.
In 2 pivotal phase 3 studies that involved more than 29 000 participants, serious side effects were similar for Shingrix and a placebo. Panelists had questions about a small but greater incidence of certain reported adverse health issues among Shingrix recipients, including gout and stroke.
GSK said it did not believe those were related to Shingrix but has proposed a post-approval safety monitoring plan.
Panelists also expressed concern that the vast majority of trial participants were white, saying they would like to see more data for other populations. 18 September 2017 (Globe Newswire)-Nabriva Therapeutics announced positive topline results from the Lefamulin Evaluation Against Pneumonia (LEAP 1) trial, which evaluated the safety and efficacy of intravenous (IV) to oral lefamulin in patients with community-acquired bacterial pneumonia (CABP).
In the LEAP 1 trial, the first of 2 pivotal phase 3 clinical trials of lefamulin in patients with CABP, lefamulin met the US Food and Drug Administration (FDA) primary endpoint of noninferiority (NI, 12.5% margin) compared to moxifloxacin with or without adjunctive linezolid for early clinical response (ECR) assessed 72 to 120 hours following initiation of therapy in the intent to treat (ITT) patient population. In the trial, ECR rates were 87.3% for lefamulin and 90.2% for N E W S ii • CID 2017:65 (1 December) • NEWS moxifloxacin with or without linezolid (treatment difference, −2.9; 95% confidence interval [CI], −8.5, 2.8).
Dr. Colin Broom, chief executive officer of Nabriva Therapeutics, said that "due to lefamulin's flexible dosing and targeted spectrum of activity against the pathogens most commonly associated with CABP, including multidrug-resistant strains, we believe that lefamulin is well suited to be a first-line empiric monotherapy. Lefamulin also met the primary endpoints for the European Medicines Agency of noninferiority (NI, 10% margin) compared to moxifloxacin with or without adjunctive linezolid in the modified ITT (mITT) and clinically evaluable at test of cure (CE-TOC) populations based on an investigator assessment of clinical response (IACR) at a test of cure visit (5 to 10 days following the completion of study therapy). IACR rates for the mITT population were 81.7% for lefamulin and 84.2% for moxifloxacin with or without linezolid (treatment difference, −2.6; 95% CI, −8.9, 3.9) and for the CE-TOC population were 86.9% for lefamulin and 89.4% for moxifloxacin with or without linezolid (treatment difference, −2.5; 95% CI, −8.4, 3.4). IACR is also a key secondary endpoint for the FDA.
In the LEAP 1 trial, a similar rate of treatment-emergent adverse events was observed in the lefamulin arm and the moxifloxacin with or without linezolid arm.
Editorial comment: Lefamulin is a pleuromutilin, a new class of antibiotics that inhibit the synthesis of bacterial protein by binding to the peptidyl transferase center on the bacterial ribosome. It is active against pneumococci, gonococci, staphylococci, legionella, mycoplasma, and chlamydia. There is little literature I could find to make any other statements. Among approximately 50 attendees, 30 (60%) completed the survey; 19 (63%) respondents met the case definition. The majority of commonly reported symptoms included diarrhea (17 of 18), abdominal pain (15 of 16), and headache (7 of 15). The median interval from lunch to illness onset was 5.3 hours (range, 0.4-15.5 hours) for any symptom and 7 hours (range, 2.5-13 hours) for diarrhea. Analysis of food exposures reported by 16 ill and 10 well respondents found illness to be associated with the beef dish (RR = undefined; confidence interval = 1.06-∞; P = 0.046). All 16 ill respondents reported eating the beef. Coffee was also associated with illness; however, all 13 coffee drinkers who became ill also ate the beef. Eating cake approached significance (P = 0.051); all 10 cake eaters who became ill also ate the beef.
The caterer had begun preparing all dishes the day before the lunch. Meats were partially cooked and then marinated in the refrigerator overnight. In the morning, they were sautéed 2 hours before lunch.
The caterer's 4 food workers reported no recent illness. Stool specimens from the food workers and from 4 ill attendees tested negative for norovirus, Campylobacter, Escherichia coli O157, Salmonella, and Shigella. Two specimens from food workers were positive for enterotoxigenic E. coli by polymerase chain reaction, but no enterotoxigenic E. coli colonies were isolated. Specimens from all attendees contained Clostridium perfringens enterotoxin.
Diarrhea and other gastrointestinal symptoms are caused by C. perfringens enterotoxin production in the intestines. Vomiting is rare and illness is usually self-limited, although type C strains can cause necrotizing enteritis.
Clostridium perfringens enterotoxin detection in the stool of 2 or more ill persons confirms C. perfringens as the outbreak etiology. Enterotoxigenic E. coli can colonize asymptomatic persons, which might explain the presence of these pathogens in the stools of asymptomatic food workers.
Clostridium perfringens outbreaks are typically associated with improper cooling or inadequate reheating of contaminated meats.
An estimated 1 million illnesses in the United States each year are attributable to C. perfringens, but fewer than 1200 illnesses are reported annually with C. perfringens outbreaks. Clostridium perfringens testing is not routine for foodborne outbreaks.
